Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.38 Analyst target: $8.00 Upside: 236.13%
Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.